Literature DB >> 16133220

[Pharmacotherapy of pituitary diseases].

B Gutt1, B Steffin, J Schopohl.   

Abstract

Successful pharmacotherapy of pituitary hormonal excess is established only in the treatment of acromegaly (dopamine agonists, somatostatin analogues, GH-receptor-antagonists) and of prolactinomas (dopamine agonists). Gold standard in the treatment of acromegaly is transsphenoidal pituitary surgery, while in prolactinomas, surgery is indicated only in exceptional cases. Substitution of pituitary insufficiency offers the patients a normal quality of life. Substitution of the cortico- and thyrotrope axis with hydrocortisone and levothyroxine is vital. In women, substitution of the gonadotrope axis should be performed up to menopause (estrogen/gestagen). In men, substitution should be performed lifelong (trans-dermal testosterone body patches, testosterone gel, testosterone undecanoate/enanthate). To achieve fertility, gonadotropins or pulsatile GnRH therapy has very good results. Especially in younger patients, substitution of growth hormone may be useful (somatropin).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16133220     DOI: 10.1007/s00108-005-1482-x

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  16 in total

1.  The daily cortisol production reinvestigated in healthy men. The serum and urinary cortisol production rates are not significantly different.

Authors:  G P Kraan; R P Dullaart; J J Pratt; B G Wolthers; N M Drayer; R De Bruin
Journal:  J Clin Endocrinol Metab       Date:  1998-04       Impact factor: 5.958

2.  Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.

Authors:  A J van der Lely ; A Muller; J A Janssen; R J Davis; K A Zib; J A Scarlett; S W Lamberts
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

3.  Cabergoline in the treatment of acromegaly: a study in 64 patients.

Authors:  R Abs; J Verhelst; D Maiter; K Van Acker; F Nobels; J L Coolens; C Mahler; A Beckers
Journal:  J Clin Endocrinol Metab       Date:  1998-02       Impact factor: 5.958

4.  Dehydroepiandrosterone replacement in women with adrenal insufficiency.

Authors:  W Arlt; F Callies; J C van Vlijmen; I Koehler; M Reincke; M Bidlingmaier; D Huebler; M Oettel; M Ernst; H M Schulte; B Allolio
Journal:  N Engl J Med       Date:  1999-09-30       Impact factor: 91.245

5.  Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system.

Authors:  S Arver; A S Dobs; A W Meikle; R P Allen; S W Sanders; N A Mazer
Journal:  J Urol       Date:  1996-05       Impact factor: 7.450

6.  Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.

Authors:  A J van der Lely; R K Hutson; P J Trainer; G M Besser; A L Barkan; L Katznelson; A Klibanski; V Herman-Bonert; S Melmed; M L Vance; P U Freda; P M Stewart; K E Friend; D R Clemmons; G Johannsson; S Stavrou; D M Cook; L S Phillips; C J Strasburger; S Hackett; K A Zib; R J Davis; J A Scarlett; M O Thorner
Journal:  Lancet       Date:  2001-11-24       Impact factor: 79.321

7.  Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly.

Authors:  J Feenstra; W W de Herder; S M T H ten Have; A W van den Beld; R A Feelders; J A M J L Janssen; A J van der Lely
Journal:  Lancet       Date:  2005 May 7-13       Impact factor: 79.321

8.  Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel).

Authors:  B Gutt; M Bidlingmaier; K Kretschmar; C Dieterle; B Steffin; J Schopohl
Journal:  Exp Clin Endocrinol Diabetes       Date:  2005-03       Impact factor: 2.949

9.  Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas.

Authors:  P Konopka; J P Raymond; R E Merceron; J Seneze
Journal:  Am J Obstet Gynecol       Date:  1983-08-15       Impact factor: 8.661

10.  Premature mortality due to cardiovascular disease in hypopituitarism.

Authors:  T Rosén; B A Bengtsson
Journal:  Lancet       Date:  1990-08-04       Impact factor: 79.321

View more
  1 in total

Review 1.  [Treatment of pituitary gland hyperfunction: from acromegaly to prolactinoma].

Authors:  A Schäffler
Journal:  Internist (Berl)       Date:  2006-12       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.